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A goal of mutagenicity testing is to de-
velop a test that detects genetic damage and
mutations with great sensitivity, and to
have this test relevant to man. No test avail-
able at the present time completely fulfills
this goal, and a variety of compromises have
been and continue to be made in test sys-
tems.
In considering cytogenetic techniques it is
quite clear that these are excellent methods
for detecting chromosomal abnormalities.
Changes in chromosome number and trans-
locations that can be heritable can be de-
tected and are significant to the human pop-
ulation. This is clear enough that it does not
require further discussion. This does not
mean that all details of this methodology
are established, but there is no disagreement
in the principle that cytogenetic tests can
supply this information. In the present pa-
per I would like to present three questions
relating to the significance of cytogenetic
abnormalities in which there is not uniform
agreement.
The iirst of these questions is whether or
not chromosome abnormalities in the form
of chromosome breaks or clastogenic events
can serve as an indicator or test system for
gene mutations. The basis of this possibility
is the high correlation between the ability
of an agent to produce gene mutations, and
its ability to produce chromosome breakage.
These correlations are seen with both x-
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irradiation and chemicals. In the case of ir-
radiation, it is exemplified by the work of
Sparrow (1), in which a linear dose re-
sponse curve is found with both single-hit
chromosome abnormalities and gene muta-
tions. With chemicals there is virtually
100% correlation between the ability of a
chemical to produce gene mutations and
its ability to produce clastogenic events.
Some data were summarized a few years
ago by Kihlman (2).
It should be pointed out that while this
general correlation between an agent's abil-
ity to produce mutagenic and clastogenic
events is true, there are defects in the quan-
titation and sensitivity of the correlations.
Thus, polyfunctional alkylating agents are
more effective chromosome breakers than
monofunctional alkylating agent, but this is
not seen in their effectiveness as mutagens.
Also, methylating agents tend to be more
effective than ethylating agents as clasto-
gens, but are less effective as producers of
gene mutations. There is also no indication
that the mechanism of production of clas-
togenic events and point mutational events
is the same. On the contrary, Freese (3)
has presented evidence that the mechanisms
are probably quite different. Furthermore,
there are very elegant tests available for
gene and point mutations as those described
by Ames (4). The prime reason for con-
sidering clastogenic effects as a possible test
for gene mutations, is the aspect of human
relevance. Chromosomal studies are the only
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in vivo testing. The question then, Is this
correlation between clastogenic and muta-
genic effects sufficient to use as a test for
gene mutations because of the high rele-
vance to man? In my view it is. This would
of course in no way replace the other tests
for gene mutations that have been suggested
for screening programs. Rather, after these
screening programs have been carried out,
at the time of human drug trial or human
exposure to a new environmental chemical,
human leukocyte chromosomes would be
studied in the exposed population. The in-
duction of clastogenic events by any new com-
pound would serve to alert to the pos-
sibility that in the human species this agent
might produce gene mutations, and this in-
formation would be utilized for appropriate
cautions, additional testing and evaluation of
the risk versus benefit.
The second question to be presented con-
cerns the significance of in vivo versus in
vitr.o cytogenetic testing. The method of
choice for cytogenetic testing is an in vivo
system, because of the problems of metabo-
lic activation of chemical compounds. How-
ever, if biologicals as virus vaccines, viral
pesticides, or disease-producing viruses are
to be evaluated in screening procedures, spe-
cial problems are encountered that are cur-
rently best solved by an in vitro system.
This relates to the species specificity ex-
hibited by many viral agents which requires
that human cells be used in testing, and
an in vitro human cell system is the most
practical current method. This question
then, relates to whether or not the risk of
genetic damage from biological material is
great enough for these to be included in
screening procedures.
The third question to be raised also re-
lates to in vivo versus in vitro testing. In
this case, the question is in relation to the
specific type of defect termed a "pseudochias-
mata" or a "side-arm bridge." It was at one
time felt that this type of abnormality
might only represent stickiness and not be
a true defect. However, electron microscopy
studies (5) have demonstrated quite con-
clusively that pseudochiasmata do represent
true abnormalities. It is difficult to recog-
nize pseudochiasmata in metaphase cells of
human origin or in mammalian cells that
have many chromosomes. These defects
are easily recognized, however, in anaphase.
As reported elsewhere, in these proceedings
(6), the anaphase test has not worked well
in in vivo systems. This test does work very
well in in vitro systems. This question then,
is whether or not the pseudochiasmata type
of defect is of sufficient significance to war-
rant the inclusion of an in, vitro anaphase
system. At the present time this is a very
difficult question to decide, since there is
very little information available on the gene-
tic significance of pseudochiasmata or side-
arm bridges. This question is raised now for
future consideration, rather than in the
hope of a solution at this time.
Summary
Three questions are presented concerning
the significance of cytogenetic abnormali-
ties and test systems for their detection.
These are: (1) Should clastogenic activity
in an in vivo human system be considered
a test for gene mutation because of the high
correlation between these two events and
relevance to man? (2) Should virus vac-
cines and biologicals be tested in vitro with
human cells? (3) Are pseudochiasmata or
side-arm bridges of sufficient significance
in patients to consider in vitro anaphase
methods for their testing?
In my view, the answers to the first two
questions are affirmative, while data for a
conclusive answer to question 3 ar enot suffi-
cient at the present time. This decision
should be deferred until a later time.
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Discussion
Dr. G. Wolff (NCTR): Even though it looked
bad for the anaphase system, I must say I was
impressed by the presentation on macronucleus
system as it showed up when erythrocytes were used.
If this sort of system would work we might have a
good in vivo system there.
Dr. Nichols: I agree completely. The micronucleus
test systems on polychromatic red blood cells appears
to be an excellent in vivo mammalian test system
that I believe should be used. I'm saying that human
leukocyctes should be used at the time of human
exposure to a new compound in addition to these
other tests.
Dr. M. S. Legator (Brown Univ.): I think we
very frequently make the mistake of talking about
in vitro or in vivo and saying we have to use one or
the other. Actually this is not what we should be
doing. Certainly nobody will ever say that because
we do an in viivo test we can't do an in vitro test.
The real issue is, can we handle a screening
operation an in vi?o procedure as well as an in vitro
prccedure and then see what the information gen-
erates. Most of the cytogenetic procedures that one
will employ will usually and very conveniently
handle both; I think that the real problem is that we
automatically say to ourselves that the in vitro
procedures are cheap and fast and therefore we
should use a kind of screening pyramid here. In
fact, I think this is the wrong way to do it. We
should try to do the in vivo procedures when they
are not completely impractical but also carry out
in vitro techniques and then assess the overall data
and not look at these things as separate categories.
Dr. Nichols: I certainly agree. What I'm really
asking, though, is are they important enough to do.
I'm not saying that facetiously; I wonder if
biologicals are important enough to require evalua-
tion. I think that they probably are. I think that
there will probably be better methods in the future
for these evaluations, but at the present time an
in vitro method with human cells is the best answer
for testing biologicals as viruses for a potential
mutagenic capacity.
Dr. W. G. Flamm (FDA): Four of us have
worked together on a document that relates to what
Dr. Nichols has said. I want to say that I agree
completely with him about the utility of the somatic
cell cytogenetic methods, insofar as it provides a
way of making comparisons from the laboratory
animal to man. I think this is a very important
thing, one of the few things we have that we can
use. With all of our talk about extrapolation I think
it is absolutely clear that we want to be able to use
it. Now the question is, do we want to apply it across
the board; would it be useful, for instance, in food
additives, and so on. My own opinion is I have not
yet identified those areas where it would be useful,
but clearly it is useful for drugs; I think that there
is probably unanimity of opinion on that point.
Dr. J. F. Crow (Univ. of Wisconsin): What's
different in principle between drugs and food ad-
ditives?
Dr. Flamm: Well, with drugs you can do epi-
demiology; you can identify exposed populations;
you can ascertain levels of exposure and kinds of
exposure when you are dealing with a chemo-
therapeutic situation, if you're in phase 1 or phase 2
of the drug study. With food additives, on the other
hand, we're asking the question about a substance
which may or may not be harmful, but is ubiquitous,
reaches us in relatively trace amounts, either in
indirect or direct food additives, or what have you,
something on which we cannot do epidemiology
because we do not have a defined human population
with a defined exposure. The relationship between
the cytogenetics and the human, I think, affords us
nothing.
Dr. S. S. Epstein (Case Western Reserve): I'm
not clear what epidemiology has to do with the
problem we're talking about. Clearly there are
tremendously difficult problems in epidemiological
analyses of adverse effects for agents to which
massive populations are exposed and to which there
are no sharp differential exposures. This is very,
very clear. It is much simpler to pick up effects in
very small populations which are exposed to single
agents than to massive populations which are
exposed to a wide variety of small level agents. I
don't understand the basic distinction you're trying
to make between drugs and other kinds of chemicals,
however. First of all, the pharmacologists and
toxicologists often use the word drug to imply any
kind of chemical agent; in fact, we talk about
animal drugs, which are really feed additives, and a
wide range of materials ranging from antibiotics to
growth hormones or stimulants are treated as animal
drugs and residues of them come through into the
diet. If you are interested in making comparisons
between effects in animals (which I think is a
terribly important thing to do) I couldn't agree with
you any more that cytogenetics is one of those few
areas which allows one to go directly from the
animal situation to the human situation. Clearly,
one can do the same with food additives and with
pe-sticides as one can for drugs. As far as materials
that are already on the market and are in ouir daily
diet, we cannot use cytogenetics in a random popula-
tion to see what their efTects are, but one can use
specific human volunteer groups, as is usual in the
December 1973 181development of any food additive or any pesticide
and see what happens from the point of view of
limited exposures at the same time as one does ones
metabolic studies one can do some limited cytogenetic
studies. I think it is very important to regard all
chemicals as a homogeneous kind of entity and not
to create artificial distinctions which reflect, it's true,
the realities of difficulties in epidemiological analysis.
Dr. Flamm: I don't want to mislead anybody in
this area with my comments where it's possible to do
work in this area. I think it should be done, and
you've identified some of the areas where it's
possible. In fact, specific suggestions would be
helpful to the agency that could subsequently be used
by epidemiologists, and, as you probably know,
attempts are being made to build a program in that
area. I would think that the cytogenetic effect is
likely to be a part of that. It certainly is going to be
consi,dered. But when we come down to GRAS
compounds it will be really hard to come up with
those matched controls that we would need to
ascertain doubling exposures.
Dr. Legator: The thing that I can't quite com-
prehend is why we need this kind of epidemiological
information in man before we declare something a
hazard.
Dr. Flamm: I'm saying the exact same thing
Dr. Nichols is saying. We're not talking about the
requirement that we look at man to say whether the
thing constitutes a hazard. I think what Dr. Nichols
is talking about is that this is the one way that we
have of understanding what relationship exists be-
tween what we do in the laboratory and what's
happening out in the human population. Now we're
not saying whether this is tantamount to making a
determination as to the safety or the hazardous
nature of the substance.
Dr. S. Abrahamson (Univ. of Wisconsin): This
looks like an area of agreement. I think that Sam
and you are now in agreement and that Marvin and
you are now in agreement.
Dr. Legator: The point I thought we were dis-
cussing here is, does cytogenetic methodology give
indication of a mutagenic event? Now, in that
context the only thing I was trying to add is that if
we find, as I do believe, that chromosomal abnormali-
ties constitute evidence of genetic hazard, and if we
find this with GRAS compounds, i.e., drugs, pesti-
cides, and cosmetics, this is an indication of a
hazardous substance and we should take the ap-
propriate action. Perhaps we're all in agreement
there.
Dr. V. A. Ray (Pfizer): There are two points.
First, what can we do when we find in experimental
animals or even in man that we have a lot of
clastogenic effects but can't match them up with any
definite mutation? What do we do when we can't find
anything, demonstrate a point mutation or demon-
strate by abnormalities in any other system that
there is realy a genetic error? That's a concern I
think. The second is what happens when you gen-
erate all data on somatic cells-a majority of
cytogenetic evaluations are on i7i vii o bone marrow,
really very little is being done on germ cells? Should
we extrapolate those data to the germ cells?
Dr. Wolff: In the first place, we heard on the
first day, in response to a question of Dr. Crow in
answer to Dr. Cummings, that many of Dr. Russell's
specific locus mutations were indeed deletions, which
means that these are just subvisible clastogenic
effects. They are the equivalent of chromosome
breaks but smaller and unlikely to be lethal (to the
cell). Thus we can relate now chromosome breakage
to an event that will be mutagenic, cause a heritable
change. The ratio of these two events, the big ones
that we can see (which will kill a cell) to the small
ones with which the cell will be viable, is still
unknown, but we can get that ratio. Once we have
that ratio, it seems to me you can tell in the mouse,
for instance, the difference between the things you
can see and those that are mutagenic. Dr. Brewen
spoke about ways in which you could now make a
further transition: to go from the things you can see
in the mouse to things you can see in the man. From
there, though it may be a bit tenuous, it seems
reasonable to assume that the ratio in mouse between
the big changes and the small ones might very well
hold. There is another thing you asked (which has
come up time and time again at this meeting): that's
the question regarding work with somatic cells. One
of the types of somatic cells that is being studied is
spermatogonia. In terms of genetic effects, these are
the cells that are at risk for a long time, because
these are the ones that keep producing the gametes
throughout the generation-30 years if you want to
take this as the genetic generation. These are the
cells that are going to be exposed over their lifetime,
whereas the mature germ cells, sperm, are only going
to last about 2 weeks and then be gone; in general,
you don't have to have as much concern about those
cells as you do about the spermatogonia which will
give rise to the mature sperm.
Dr. M. Shaw (Anderson Hospital): It doesn't
really matter to me whether a person becomes
mentally retarded or has a general defect or gets
cancer because cf a clastogen rather than a mutagen.
I think that it's still a hazard.
Dr. E. Freese (NINDS-NIH): I'd like to em-
phasize that the ratio between the point mutagenic
effect and the chromosome-breaking effect may be as
much as a factor of 10,000 for some agents. For
some agents we have low ratios, for others we have
high ratios. Although Dr. Nichols' method may be
useful, I think we have to make very sure that point
mutagenic tests are also done. In addition, Dr.
Nichols himself had told me that the measles virus is
amazing, because it produces chromosome breaks but
does not seem to cause cancer or mutations. I
thought the reason for this finding was that any cell
which is infected by the measles virus suffers so
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that ,ase, Dr. Nichols' test might predict more
mutagenic harm than actually exists.
Dr. Nichols: I didn't really mean to say that;
that is bad communication on my part. I think that a
disease like measles is so common in the population-
something like 99'/c-that we just can't tell what its
relation is to cancer or mutation. Certainly most of
the lymphocytes we see with damage would result in
dead cells but not in all of them.
Dr. Mauer (Hoffman-LaRoche Inc.): I would
like to put a caveat in here. That's the fact that
many of the in vitro tests are run at rather toxic
dosages. Obviously, if you don't take cell survival or
some other indication like mitotic index, everything
will be clastogenic but not necessarily mutagenic. We
can't (operationally at least) measure these small
chromosomal effects, and that applies to the in vitro
situation. Of course, we see a lot in the literature on
in vivo level at enormous dosages which are toxic in
the animal to the bone marrow cells, and that should
be taken into consideration.
Dr. B. Ames (Univ. of California, Berkeley): It
might be interesting to try some of these reactive
intercalator-type frame shift mutations in some of
these other tests; in other words, to use some
activated afltoxins which are easy to make or
activated benzpyrene in some of these chromosome
break tests.
Dr. Legator: They have been used.
Dr. L. Friedman (FDA): On the question of
epidemiology, I would think everyone here is in
agreement. We do need to have epidemiology for the
purpose of surveillance to see whether something's
gone wrong or whether we can identify the agent. In
the general sense I think that's very important.
That's one kind of program for which we need
methods and for which we hope the methods will be
developed. The use of humans, however, is not
epidemiology; this is human study with defined
populations and under known areas of exposure. This
also should be done whenever we think we have tests
that are relevant. It will be inevitable that we make
choices, because we can't do everything at the same
time. I just want to point out that an essential
difference between therapeutic agents and other
environmental low level agents is that therapeutic
agents or diagnostic agents are used by their very
nature at biologically effective levels-else why use
them. Because of this difference, and everything else
we are concerned about, it would seem to me they
would have some priority for testing.
Dr. Nichols: To respond to Dr. Mauer, with re-
spect to clastogenic effects, when human exposure is
started with a new agent whether industrial, drug,
or food additive, I believe if it's a new agent-even
if it's passed all previous tests-if its a clastogen in
humans then I would consider it a mutagen. I'm
taking the situation where it's passed all the animal
testing. We have several good plans which should be
used and better tests for gene mutations than
clastogenic effects, but I do agree with what Dr.
Shaw said about clastogenic effects.
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